Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

Most CRS, ICANS, and neuro events after liso-cel were mild and occurred within 15 days post-infusion, according to different ...

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Analyzing DNA methylation patterns in leukemic cells is helping doctors better assess risk and tailor treatments, making ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

Chronic lymphocytic leukemia (CLL) is a cancer that affects ... CLL can get worse and become a more aggressive cancer called diffuse large B-cell lymphoma, also called Richter's syndrome or ...

a disease which cannot be fully understood when considered just as simple B-cell monoclonal malignancy. The Surveillance E, and End Results (SEER) Program of the National Cancer Institute, Cancer Stat ...

Chronic lymphocytic leukemia (CLL) is a type of cancer that happens when a person’s bone marrow makes too many lymphocytes, one of the types of white blood cells that help your body fight infection.